TAMOXIFEN VERSUS CHEMOTHERAPY AS ADJUVANT TREATMENT IN STAGE III BREAST CANCER

Publisher Website
Google Scholar
Abstract
A randomzied prospective trial was conducted to compare Tamoxifen and combination chemotherpy (5-fluorouracil, doxorubicin and cyclophosphamide) as adjuvant treatment for patients with locally advanced (Stage III) breast cancer. At the end of 5 years, no significant difference could be found in the disease-free period for both groups.